Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01

J. M. LeClerc, A. L. Billett, R. D. Gelber, V. Dalton, N. Tarbell, J. M. Lipton, R. Barr, L. A. Clavell, B. Asselin, C. Hurwitz, M. Schorin, Steven E Lipshultz, L. Declerck, L. B. Silverman, H. J. Cohen, S. E. Sallan

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic leukemia. Patients and Methods: Patients from all risk groups, including infants and those with T-cell disease, were treated between 1987 and 1991. Standard-risk (SR) patients did not receive cranial irradiation, whereas high-risk (HR) and very high-risk (VHR) patients participated in a randomized comparison of 18 Gy of cranial irradiation conventionally fractionated versus two fractions per day (hyperfractionated). Results: At a median follow-up of 9.2 years, the 9-year event-free survival (EFS ± SE) was 75% ± 2% for all 369 patients, 77% ± 4% for the 142 SR patients, and 73% ± 3% for the 227 HR/VHR patients (P = .37 comparing SR and HR/VHR). The CNS, with or without concomitant bone marrow involvement, was the first site of relapse in 19 (13%) of the 142 SR patients: 16 (20%) of 79 SR boys and three (5%) of 63 SR girls. This high incidence of relapses necessitated a recall of SR boys for additional therapy. CNS relapse occurred in only two (1%) of 227 HR and VHR patients. There were no outcome differences found among randomized treatment groups. Nine-year overall survival was 84% ± 2% for the entire population, 93% ± 2% for SR children, and 79% ± 3% for HR and VHR children (P < .01 comparing SR and HR/VHR). Conclusion: A high overall survival outcome was obtained for SR patients despite the high risk of CNS relapse for SR boys, which was presumed to be associated with eliminating cranial radiation without intensifying systemic or intrathecal chemotherapy. For HR/VHR patients, inability to salvage after relapse (nearly all of which were in the bone marrow) remains a significant clinical problem.

Original languageEnglish
Pages (from-to)237-246
Number of pages10
JournalJournal of Clinical Oncology
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Recurrence
Cranial Irradiation
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

LeClerc, J. M., Billett, A. L., Gelber, R. D., Dalton, V., Tarbell, N., Lipton, J. M., ... Sallan, S. E. (2002). Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01. Journal of Clinical Oncology, 20(1), 237-246. https://doi.org/10.1200/JCO.20.1.237

Treatment of childhood acute lymphoblastic leukemia : Results of Dana-Farber ALL Consortium Protocol 87-01. / LeClerc, J. M.; Billett, A. L.; Gelber, R. D.; Dalton, V.; Tarbell, N.; Lipton, J. M.; Barr, R.; Clavell, L. A.; Asselin, B.; Hurwitz, C.; Schorin, M.; Lipshultz, Steven E; Declerck, L.; Silverman, L. B.; Cohen, H. J.; Sallan, S. E.

In: Journal of Clinical Oncology, Vol. 20, No. 1, 01.01.2002, p. 237-246.

Research output: Contribution to journalArticle

LeClerc, JM, Billett, AL, Gelber, RD, Dalton, V, Tarbell, N, Lipton, JM, Barr, R, Clavell, LA, Asselin, B, Hurwitz, C, Schorin, M, Lipshultz, SE, Declerck, L, Silverman, LB, Cohen, HJ & Sallan, SE 2002, 'Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01', Journal of Clinical Oncology, vol. 20, no. 1, pp. 237-246. https://doi.org/10.1200/JCO.20.1.237
LeClerc, J. M. ; Billett, A. L. ; Gelber, R. D. ; Dalton, V. ; Tarbell, N. ; Lipton, J. M. ; Barr, R. ; Clavell, L. A. ; Asselin, B. ; Hurwitz, C. ; Schorin, M. ; Lipshultz, Steven E ; Declerck, L. ; Silverman, L. B. ; Cohen, H. J. ; Sallan, S. E. / Treatment of childhood acute lymphoblastic leukemia : Results of Dana-Farber ALL Consortium Protocol 87-01. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 1. pp. 237-246.
@article{ab2a3850ad174646b7de8cf9ef9ed7ad,
title = "Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01",
abstract = "To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic leukemia. Patients and Methods: Patients from all risk groups, including infants and those with T-cell disease, were treated between 1987 and 1991. Standard-risk (SR) patients did not receive cranial irradiation, whereas high-risk (HR) and very high-risk (VHR) patients participated in a randomized comparison of 18 Gy of cranial irradiation conventionally fractionated versus two fractions per day (hyperfractionated). Results: At a median follow-up of 9.2 years, the 9-year event-free survival (EFS ± SE) was 75{\%} ± 2{\%} for all 369 patients, 77{\%} ± 4{\%} for the 142 SR patients, and 73{\%} ± 3{\%} for the 227 HR/VHR patients (P = .37 comparing SR and HR/VHR). The CNS, with or without concomitant bone marrow involvement, was the first site of relapse in 19 (13{\%}) of the 142 SR patients: 16 (20{\%}) of 79 SR boys and three (5{\%}) of 63 SR girls. This high incidence of relapses necessitated a recall of SR boys for additional therapy. CNS relapse occurred in only two (1{\%}) of 227 HR and VHR patients. There were no outcome differences found among randomized treatment groups. Nine-year overall survival was 84{\%} ± 2{\%} for the entire population, 93{\%} ± 2{\%} for SR children, and 79{\%} ± 3{\%} for HR and VHR children (P < .01 comparing SR and HR/VHR). Conclusion: A high overall survival outcome was obtained for SR patients despite the high risk of CNS relapse for SR boys, which was presumed to be associated with eliminating cranial radiation without intensifying systemic or intrathecal chemotherapy. For HR/VHR patients, inability to salvage after relapse (nearly all of which were in the bone marrow) remains a significant clinical problem.",
author = "LeClerc, {J. M.} and Billett, {A. L.} and Gelber, {R. D.} and V. Dalton and N. Tarbell and Lipton, {J. M.} and R. Barr and Clavell, {L. A.} and B. Asselin and C. Hurwitz and M. Schorin and Lipshultz, {Steven E} and L. Declerck and Silverman, {L. B.} and Cohen, {H. J.} and Sallan, {S. E.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1200/JCO.20.1.237",
language = "English",
volume = "20",
pages = "237--246",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Treatment of childhood acute lymphoblastic leukemia

T2 - Results of Dana-Farber ALL Consortium Protocol 87-01

AU - LeClerc, J. M.

AU - Billett, A. L.

AU - Gelber, R. D.

AU - Dalton, V.

AU - Tarbell, N.

AU - Lipton, J. M.

AU - Barr, R.

AU - Clavell, L. A.

AU - Asselin, B.

AU - Hurwitz, C.

AU - Schorin, M.

AU - Lipshultz, Steven E

AU - Declerck, L.

AU - Silverman, L. B.

AU - Cohen, H. J.

AU - Sallan, S. E.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic leukemia. Patients and Methods: Patients from all risk groups, including infants and those with T-cell disease, were treated between 1987 and 1991. Standard-risk (SR) patients did not receive cranial irradiation, whereas high-risk (HR) and very high-risk (VHR) patients participated in a randomized comparison of 18 Gy of cranial irradiation conventionally fractionated versus two fractions per day (hyperfractionated). Results: At a median follow-up of 9.2 years, the 9-year event-free survival (EFS ± SE) was 75% ± 2% for all 369 patients, 77% ± 4% for the 142 SR patients, and 73% ± 3% for the 227 HR/VHR patients (P = .37 comparing SR and HR/VHR). The CNS, with or without concomitant bone marrow involvement, was the first site of relapse in 19 (13%) of the 142 SR patients: 16 (20%) of 79 SR boys and three (5%) of 63 SR girls. This high incidence of relapses necessitated a recall of SR boys for additional therapy. CNS relapse occurred in only two (1%) of 227 HR and VHR patients. There were no outcome differences found among randomized treatment groups. Nine-year overall survival was 84% ± 2% for the entire population, 93% ± 2% for SR children, and 79% ± 3% for HR and VHR children (P < .01 comparing SR and HR/VHR). Conclusion: A high overall survival outcome was obtained for SR patients despite the high risk of CNS relapse for SR boys, which was presumed to be associated with eliminating cranial radiation without intensifying systemic or intrathecal chemotherapy. For HR/VHR patients, inability to salvage after relapse (nearly all of which were in the bone marrow) remains a significant clinical problem.

AB - To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic leukemia. Patients and Methods: Patients from all risk groups, including infants and those with T-cell disease, were treated between 1987 and 1991. Standard-risk (SR) patients did not receive cranial irradiation, whereas high-risk (HR) and very high-risk (VHR) patients participated in a randomized comparison of 18 Gy of cranial irradiation conventionally fractionated versus two fractions per day (hyperfractionated). Results: At a median follow-up of 9.2 years, the 9-year event-free survival (EFS ± SE) was 75% ± 2% for all 369 patients, 77% ± 4% for the 142 SR patients, and 73% ± 3% for the 227 HR/VHR patients (P = .37 comparing SR and HR/VHR). The CNS, with or without concomitant bone marrow involvement, was the first site of relapse in 19 (13%) of the 142 SR patients: 16 (20%) of 79 SR boys and three (5%) of 63 SR girls. This high incidence of relapses necessitated a recall of SR boys for additional therapy. CNS relapse occurred in only two (1%) of 227 HR and VHR patients. There were no outcome differences found among randomized treatment groups. Nine-year overall survival was 84% ± 2% for the entire population, 93% ± 2% for SR children, and 79% ± 3% for HR and VHR children (P < .01 comparing SR and HR/VHR). Conclusion: A high overall survival outcome was obtained for SR patients despite the high risk of CNS relapse for SR boys, which was presumed to be associated with eliminating cranial radiation without intensifying systemic or intrathecal chemotherapy. For HR/VHR patients, inability to salvage after relapse (nearly all of which were in the bone marrow) remains a significant clinical problem.

UR - http://www.scopus.com/inward/record.url?scp=0036138779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036138779&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.1.237

DO - 10.1200/JCO.20.1.237

M3 - Article

C2 - 11773175

AN - SCOPUS:0036138779

VL - 20

SP - 237

EP - 246

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -